LABORATORY RESEARCH Molecular Characterization of the Tumor-Suppressive Function of Nischarin in Breast Cancer Nischarin (encoded by NISCH), an α5 integrin–binding protein, has been identified as a regulator of breast cancer cell invasion. Scientists hypothesized that it might be a tumor suppressor and were interested in its regulation. [J Natl Cancer Inst] Abstract | Press Release Hypoxia-Inducible Factor 1 Is a Master Regulator of Breast Cancer Metastatic Niche Formation Here, researchers demonstrate that hypoxia-inducible factor 1 is a critical regulator of breast cancer metastatic niche formation through induction of multiple members of the lysyl oxidase (LOX) family, including LOX, LOX-like 2, and LOX-like 4, which catalyze collagen cross-linking in the lungs before bone marrow-derived cell recruitment. [Proc Natl Acad Sci U S A] Abstract Integrated Molecular Profiles of Invasive Breast Tumors and Ductal Carcinoma In Situ Reveal Differential Vascular and Interleukin Signaling Investigators use an integrated approach to understand breast cancer heterogeneity by modeling mRNA, copy number alterations, microRNAs, and methylation in a pathway context utilizing the pathway recognition algorithm using data integration on genomic models. [Proc Natl Acad Sci U S A] Abstract Breast Cancer Subtype Specific Interactions with the Microenvironment Dictate Mechanisms of Invasion Here scientists report that co-culture of mammary fibroblasts specifically triggers invasive behavior in basal-type breast cancer cells through a ligand independent mechanism. [Cancer Res] Abstract SIRT1 Is Essential for Oncogenic Signaling by Estrogen/Estrogen Receptor α in Breast Cancer In this study, researchers show that SIRT1 is critical for estrogen to promote breast cancer. [Cancer Res] Abstract A Kinome-Wide Screen Identifies the Insulin/IGF-1 Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer In this study, investigators sought to identify kinases essential for growth of estrogen receptor α positive breast cancer cells resistant to long term estrogen deprivation. [Cancer Res] Abstract CLINICAL RESEARCH Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14 This trial was undertaken to assess whether octreotide would lower insulin and insulin-like growth factor-1 levels and reduce risk of breast cancer recurrence. [J Clin Oncol] Abstract Phase III Study of Doxorubicin/Cyclophosphamide with Concomitant Versus Sequential Docetaxel as Adjuvant Treatment in Patients with Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 Trial Scientists performed an adjuvant trial to compare the sequential regimen of doxorubicin with cyclophosphamide followed by docetaxel with the combination regimen of TAC. [J Clin Oncol] Abstract A Phase II Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer A phase II trial of dasatinib, a potent oral tyrosine kinase inhibitor of SRC-family kinases, was performed in patients with human epidermal growth factor receptor 2-positive (HER2+) and/or hormone receptor-positive advanced breast cancer. [Clin Cancer Res] Abstract |